Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ocugen stock in Canada | $9.34

Own Ocugen shares in just a few minutes.

Ocugen Inc
NASDAQ: OCGN - USD
BIOTECHNOLOGY
$9.34
+ $1.02 ( + 12.26%)

Ocugen is a biotechnology business based in the US. Ocugen stocks (OCGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.65 – an increase of 12.12% over the previous week. Ocugen employs 15 staff and has a market cap (total outstanding stock value) of $1.7 billion.

How to buy shares in Ocugen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OCGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Ocugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Ocugen's stock price?

Since the stock market crash in March caused by coronavirus, Ocugen's stock price has had significant positive movement.

Its last market close was $9.34, which is 94.46% up on its pre-crash value of $0.517 and 3,492.31% up on the lowest point reached during the March crash when the stocks fell as low as $0.26.

If you had bought $1,000 worth of Ocugen stocks at the start of February 2020, those stocks would have been worth $553.46 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $17,961.57.

Ocugen stock price

Use our graph to track the performance of OCGN stocks over time.

Ocugen shares at a glance

Information last updated 2021-10-23.
Latest market close$9.34
52-week range$0.25 - $16.20
50-day moving average $7.70
200-day moving average $7.92
Wall St. target price$8.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.27

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
FREE TRADES
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get 2 free stocks when you open a Wealthsimple Trade personal account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
OFFER
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until December 31, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Ocugen price performance over time

Historical closes compared with the close of $9.34 from 2021-10-25

1 week (2021-10-19) 12.12%
1 month (2021-09-22) N/A
3 months (2021-07-26) 36.95%
6 months (2021-04-26) -19.41%
1 year (2020-10-26) 2,938.39%
2 years (2019-10-25) 430.68%
3 years (2018-10-26) 1,091.48%
5 years (2016-10-26) 214.48%

Ocugen financials

Operating margin TTM 10146504%
Gross profit TTM $-5,099,160
Return on assets TTM -32.56%
Return on equity TTM -72.19%
Profit margin 0%
Book value $0.59
Market capitalisation $1.7 billion

TTM: trailing 12 months

Shorting Ocugen shares

There are currently 53.1 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 0.6% up from 52.8 million last month.

There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.

Ocugen's "short interest ratio" (SIR)

Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 12.0 million). Ocugen's SIR currently stands at 4.42. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 4420 shares are currently held short.

However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.27% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 270 shares are currently held short) or 0.2743% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 274 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.

Ocugen share dividends

We're not expecting Ocugen to pay a dividend over the next 12 months.

Have Ocugen's shares ever split?

Ocugen's shares were split on a 1:60 basis on 30 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.

Ocugen share price volatility

Over the last 12 months, Ocugen's shares have ranged in value from as little as $0.2501 up to $16.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocugen's is 4.3003. This would suggest that Ocugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Ocugen overview

Ocugen, Inc. , a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Stocks similar to Ocugen

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site